Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet, Intellia has a very long way to go before it has a chance to commercialize any of its product candidates, and there's nothing to suggest it's on the verge of suddenly hitting the lottery and bringing in hundreds of millions in revenue.

So what are the analysts getting at with their estimates, and should you buy this stock? 

Intellia's pipeline has two focuses, both of which pertain to its use of gene-editing technologies to treat or cure illnesses. 

Continue reading

Source Fool.com